This federal contract IDV award is for the supply of ranibizumab ophthalmic injections to the Department of Veterans Affairs (VA), Bureau of Prisons (BOP), and Indian Health Service (IHS). The single-award indefinite delivery contract, valued at $11,392,063.40, was issued by the VA National Acquisition Center to the prime contractor Biogen U.S. Corporation, a for-profit pharmaceutical manufacturer. The contract has a performance period from December 23, 2023, through December 22, 2025, with four one-year option periods.
The original solicitation, 36E79723R0018, sought offers for two product groups of ranibizumab 0.3mg/0.05ml and 0.5mg/0.05ml injections, with a total estimated annual usage of 5,732 and 1,287 units, respectively. The solicitation was unrestricted, allowing any responsible offeror to compete. Proposed biosimilar products were required to be FDA-approved and listed in the Purple Book. Offerors also needed to have an executed Master Agreement and Pharmaceutical Pricing Agreement on file with the VA National Acquisition Center to be considered for award.
Generated 2/1/25, 9:05 AM